Sharing-our-perspective-page-header2

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward



  • New York Workers’ Compensation Board provides additional clarification on mandated drug formulary notifications

    by
    • Optum for Workers' Compensation
    | Aug 15, 2019
    Tag Icon
    Pharmacy, New York, Government Affairs, formulary, Clinical
    The New York State Workers’ Compensation Board (WCB) has released information on how to implement the mandated communications to claimants and their prescribers who will be impacted when the new drug formulary goes into effect in December 2019.


  • New York announces process for payers to access the Drug Formulary Prior Authorization System

    by
    • Optum for Workers' Compensation
    | Aug 06, 2019
    Tag Icon
    Pharmacy, Clinical, Government Affairs, New York, formulary
    The New York State Workers Compensation Board (WCB) has released information on how to access and use the Drug Formulary Prior Authorization System. This is a web-based application to support the new drug formulary. It will be accessible on the WCB website and medical portal.


  • 5 Advanced Ways Clinical Expertise Can Improve Workers’ Comp Outcomes

    by
    • Optum for Workers' Compensation
    | Aug 01, 2019
    Tag Icon
    PBM, Clinical Intervention, Clinical
    Caring for injured workers should involve more than just processing transactions. Applying a clinical approach from the onset of an injury ensures more appropriate care and better outcomes.


  • States continue to approve medical marijuana ―
    could this open the door to use in workers’ comp?

    by
    • Kevin Tribout
    • Adam Fowler
    • Optum for Workers' Compensation
    | Jul 31, 2019
    Tag Icon
    Pharmacy, Pain Management, Workers' Compensation, Clinical, Chronic Pain, Government Affairs, Medical Marijuana
    More and more states are reversing course and expanding support for medical marijuana, even though, not that long ago, these states disapproved of it. Could the groundswell of support among states for medical marijuana open the door to use in workers’ comp? Read more on our blog.


  • FDA approves first alternative medications to Lyrica (pregabalin)

    by
    • Optum for Workers' Compensation
    | Jul 22, 2019
    Tag Icon
    Workers' Compensation, workers compensation, Medicare Insights, Settlement Solutions, Pain Management, Lyrica, Clinical
    Much anticipated alternative medications for Lyrica® (pregabalin) were approved by the U.S. Food and Drug Administration (FDA) on July 19, 2019. This approval follows a six-month delay announced last year. Pregabalin is an anticonvulsant with FDA approval to treat neuropathic (nerve) pain associated with diabetes, postherpetic neuralgia (shingles), fibromyalgia and neuropathic pain associated with spinal cord injury. In addition, it is approved as adjunct therapy for the treatment of partial onset seizures.


  • Texas governor signs opioid control legislation

    by
    | Jun 21, 2019
    Tag Icon
    Pain Management, Pharmacy, Government Affairs, Opioids
    A new Texas law to curb opioid abuse includes prescribing restrictions for opioid treatment of acute pain. Effective September 1, 2019, when prescribing for treatment of acute pain, a provider may not prescribe opioids for more than a 10-day supply or refill an opioid.


  • Colorado doctors can now recommend medical marijuana as opioid alternative

    by
    | Jun 13, 2019
    Tag Icon
    Clinical Intervention, Clinical, Opioids, Government Affairs, Medical Marijuana
    The Colorado legislature has passed a law permitting physicians to recommend marijuana in lieu of opioids to treat certain disabling medical conditions. Senate Bill 13, gives providers greater leeway in discussing pain treatment options with their patients and is scheduled to take effect August 2, 2019.



Stay informed by receiving latest updates

Do you have a question about a blog post?

See more insights